Factor VIII (FVIII) treatment has more than
50 years of use and over 175 clinical studies.1,2
Count on factor VIII (FVIII) prophylaxis to be there.
Your patients are unique-so they
deserve an individualized treatment.
Establishing a routine with
Factor VIII (FVIII) may
empower patients.
HELP HEMOPHILIA A PATIENTS TAKE CHARGE OF THEIR TREATMENT WITH FVIII
FVIII prophylaxis may empower patients to establish a routine with the support of their care team. After shaping a routine together, talk with your patients about ways to help them estimate their level of bleed coverage. Understanding their levels can help them make more informed observations about their physical activities — an important hallmark for self-management.1
"You really see your potential when you lean into your treatment routine, take on that responsibility."
- Pete, patient with hemophilia A
Encourage adherence
That sort of pride in ownership over their routine, of knowing where they stand with an approximation of their levels, also may encourage adherence in patients. The more they participate in helping to shape their individualized routine with their care team, the more likely they may follow through on it.2
Patient Resources
There are a number of advocacy organizations that can help connect your patients to more information or even to other members of the hemophilia community.
By following the links above you will be leaving a Takeda controlled website for a third-party website. Please note that Takeda is not responsible or liable for any third-party website and the website may not be appropriate for all audiences.
The Takeda Commitment
Takeda has been dedicated to pursuing advancements in hemophilia for more than 70 years and is proud to be a leader in hemophilia research.3
References:
1. Álvarez-Román MT, Fernandez-Bello I, de La Corte-Rodríguez H, et al. Experience of tailoring prophylaxis using factor VIII pharmacokinetic parameters estimated with myPKFiT® in patients with severe haemophilia A without inhibitors. Haemophilia. 2017;23(1):e50-e57. 2. Khair K. Minimizing joint damage: the role of nurses in promoting adherence to hemophilia treatment. Orthop Nurs. 2010;29(3):193-200. 3. Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 2019. Takeda Pharmaceuticals. December 9, 2019. Accessed September 30, 2021. https://www.takeda.com/newsroom/newsreleases/2019/takeda-demonstrates-its-long-standing-commitment/#about-takeda-hematology